ALZN Stock Discussion

Alzamend Neuro, Inc. Description

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biology Medication Neuroscience Alzheimer's Disease Neurodegenerative Diseases Dementia Psychiatric Diagnosis Amyloidosis Neurodegeneration Preclinical Stage Biopharmaceutical Psychiatric Disorders Treatment Of Neurodegenerative Diseases Treatment Of Alzheimer's